Share on StockTwits

Immune Pharmaceuticals (NASDAQ:IMNP) announced its earnings results on Thursday. The company reported ($0.35) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.15) by $0.20, Analyst RN reports.

Shares of Immune Pharmaceuticals (NASDAQ:IMNP) opened at 2.652 on Thursday. Immune Pharmaceuticals has a 52-week low of $1.15 and a 52-week high of $5.65. The stock has a 50-day moving average of $3.51 and a 200-day moving average of $3.09. The company’s market cap is $36.3 million.

A number of analysts have recently weighed in on IMNP shares. Analysts at Chardan Capital initiated coverage on shares of Immune Pharmaceuticals in a research note on Wednesday, May 14th. They set a “buy” rating and a $11.00 price target on the stock. Analysts at Zacks reiterated an “outperform” rating on shares of Immune Pharmaceuticals in a research note on Monday, March 10th. They now have a $9.00 price target on the stock.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.